Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Susanna Y. Cheng"'
Autor:
Michael C. Tjong, Malavan Ragulojan, Ian Poon, Alexander V. Louie, Susanna Y. Cheng, Mark Doherty, Liying Zhang, Yee Ung, Patrick Cheung, Parneet K. Cheema
Publikováno v:
Current Oncology, Vol 29, Iss 1, Pp 221-230 (2022)
Background: The safety impact of radiotherapy (RT) timing relative to immune checkpoint inhibitors (ICIs) for advanced non-small-cell lung cancer (NSCLC) is unclear. We investigated if RT within 14 days (Interval 1) and 90 days (Interval 2) of ICI us
Externí odkaz:
https://doaj.org/article/0edf7c18457b4be1af3cf8d0a7cec179
Autor:
Srikala S. Sridhar, Nicholas Power, Rodney H. Breau, Susanna Y. Cheng, Gregory Russell Pond, Peter W. M. Chung, Ur Metser, Mark Norman Levine, Som D. Mukherjee
Publikováno v:
Journal of Clinical Oncology. 41:460-460
460 Background: Muscle invasive bladder cancer (MIBC) is an aggressive local disease where initial staging with conventional CT imaging is often suboptimal. To explore the role of PET-CT in both staging MIBC and assessing response to neoadjuvant chem
Autor:
Rafael Morales-Barrera, Daniel E. Castellano, Peter H. O'Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Kylea R. Potvin, Susanna Y. Cheng, Eli Rosenbaum, Noah M. Hahn, Daniel Keizman, Fausto Roila, Jose Luis Perez-Gracia, Elizabeth R. Plimack, Ronald De Wit, Jin Zhi Xu, Kentaro Imai, Haojie Li, Josephine M. Norquist, Joaquim Bellmunt
Publikováno v:
Journal of Clinical Oncology. 40:4561-4561
4561 Background: Frontline cisplatin-based chemotherapy improves survival in patients (pts) with UC, but ̃50% are cisplatin-ineligible owing to poor performance status or comorbidity. The definition of platinum ineligibility is not standardized; hen
Autor:
Tibor Csoszi, Thomas Powles, Ajjai Shivaram Alva, Daniel E. Castellano, Mustafa Ozguroglu, Peter H. O'Donnell, Yohann Loriot, Noah M. Hahn, Aude Flechon, Alejo Rodriguez-Vida, Ronald De Wit, Susanna Y. Cheng, Stephane Oudard, Christof Vulsteke, Evan Y. Yu, Jianxin Lin, Kentaro Imai, Blanca Homet Moreno, Arjun Vasant Balar, Petros Grivas
Publikováno v:
Journal of Clinical Oncology. 40:521-521
521 Background: First-line treatment with pembrolizumab (pembro) monotherapy has shown durable clinical activity in selected patients (pts) with advanced/unresectable or metastatic urothelial carcinoma (UC). In a pooled population of pts with advance
Autor:
Rafael Morales-Barrera, Thomas Powles, Mustafa Ozguroglu, Tibor Csoszi, Yohann Loriot, Aude Flechon, Nobuaki Matsubara, Alejo Rodriguez-Vida, Lajos Geczi, Susanna Y. Cheng, Yves Fradet, Stephane Oudard, Seyda Gunduz, Junshui Ma, Mohini Rajasagi, Amir Vajdi, Razvan Cristescu, Kentaro Imai, Blanca Homet Moreno, Ajjai Shivaram Alva
Publikováno v:
Journal of Clinical Oncology. 40:540-540
540 Background: The 3-arm, open-label, phase 3 KEYNOTE-361 study (NCT02853305) evaluated first-line pembro ± chemo vs chemo in advanced UC regardless of PD-L1 status. The trial did not meet its primary end points of superior PFS and OS with pembro +
Publikováno v:
Current oncology (Toronto, Ont.). 27(4)
Background: Despite initial promising results, the IMvigor211 clinical trial failed to demonstrate an overall survival (OS) benefit for atezolizumab compared with chemotherapy as second-line treatment for metastatic bladder cancer (mBC). However, giv
Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib
Publikováno v:
Supportive Care in Cancer. 27:1029-1039
Afatinib is a standard first-line therapy for advanced EGFR-positive NSCLC. We implemented a pharmacist-led proactive follow-up algorithm to identify and manage early afatinib-related adverse events (AEs). We conducted a retrospective chart review of
Autor:
Brandon S. Sheffield, Natasha B. Leighl, Andrea S. Fung, Parneet Cheema, David M. Hwang, Danilo Giffoni de Mello Morais Mata, Susanna Y. Cheng, Kirstin Perdrizet, Frances A. Shepherd, Penelope A. Bradbury, Adrian G. Sacher, S. Lau, Geoffrey Liu, Ming-Sound Tsao
Publikováno v:
Journal of Clinical Oncology. 39:e21123-e21123
e21123 Background: The treatment landscape for patients with metastatic non-small cell lung cancer (mNSCLC) with a MET exon 14 skipping mutation ( MET ex14) is rapidly changing, with recent approvals of MET selective tyrosine kinase inhibitors (TKIs)
Autor:
Joseph Perera, Simon Raphael, Parneet Cheema, Ines B Menjak, Sunil Verma, Matthew Anaka, Nevkeet Toor, Susanna Y Cheng, Ryan Freedman, Zoe Winterton-Perks, J. Charles Victor, Ahmad Muinuddin
Publikováno v:
Journal of Oncology Practice. 13:e130-e138
Purpose: Optimal first-line systemic therapy for patients with advanced nonsquamous (nonsq) non–small-cell lung cancer (NSCLC) requires confirmation of EGFR/ ALK status, which can delay treatment. We evaluated the impact of reflex testing, defined
Autor:
Yves Fradet, Evan Y. Yu, Alejo Rodriguez-Vida, Yohann Loriot, Seyda Gunduz, Aude Flechon, Tibor Csőszi, Ronac Mamtani, Thomas Powles, Mustafa Ozguroglu, Kijoeng Nam, Nobuaki Matsubara, Blanca Homet Moreno, Ajjai Alva, Lajos Géczi, Stéphane Oudard, Susanna Y. Cheng, Rafael Morales-Barrera, Kentaro Imai, Christof Vulsteke
Publikováno v:
Journal of Clinical Oncology. 39:450-450
450 Background: 1L pembro is approved in advanced UC for cisplatin-ineligible pts with PD-L1 combined positive score (CPS) ≥10 and any platinum-ineligible pts regardless of CPS in the United States based on single-arm trial data. In the phase III K